Selenium Supplementation

Overview

Selenium supplementation provides the essential trace element required for synthesis of 25 human selenoproteins, including the glutathione peroxidase family (GPX1-4), thioredoxin reductases (TrxR1-3), and iodothyronine deiodinases (DIO1-3). The thyroid gland has the highest selenium concentration per gram of any human organ, making thyroid autoimmune conditions the primary indication.

> Clinical disclaimer: Selenium has a narrow therapeutic window. The difference between therapeutic dose (200 ug/day) and toxicity threshold (400 ug/day) is only 2x. All supplementation should include baseline and follow-up serum selenium monitoring.

—-

Mechanism of Action

Selenium is incorporated as selenocysteine (the "21st amino acid") into selenoproteins via a unique UGA codon recoding mechanism. Key functional classes:

  • GPX1-4: Reduce hydrogen peroxide and lipid hydroperoxides, protecting cell membranes from oxidative damage
  • TrxR1-3: Regenerate thioredoxin, maintaining intracellular redox balance and regulating NF-kB signaling
  • DIO1-3: Catalyze T4→T3 conversion (DIO1/2) and T4/T3 inactivation (DIO3), governing thyroid hormone metabolism

In selenium deficiency, these enzymes lose function in a hierarchical manner — brain and endocrine tissues are protected last, but thyroid GPX activity drops early, increasing vulnerability to hydrogen peroxide-mediated autoimmune attack.

—-

Dosage and Administration

ParameterRecommendation
FormSelenomethionine (best absorbed, most studied in RCTs)
Therapeutic dose200 ug/day for autoimmune thyroid conditions
Maintenance dose55-100 ug/day (varies by baseline status)
DurationMinimum 3 months for anti-TPO response; 6-12 months for full assessment
Upper limit400 ug/day (includes dietary intake)
Dietary sourcesBrazil nuts (1-2 nuts = ~100 ug; highly variable by soil), seafood, organ meats

—-

Monitoring

  • Serum selenium: Baseline and at 3 months. Target range 100-130 ng/mL. Below 70 ng/mL indicates deficiency; above 150 ng/mL increases toxicity risk.
  • Anti-TPO antibodies: For hashimotos thyroiditis — check at baseline, 3 months, 6 months.
  • Cu/Se ratio: For cardiovascular risk assessment. Elevated ratio warrants selenium repletion before copper reduction.
  • Selenosis signs: Monitor for garlic breath, brittle nails/hair, GI disturbance, peripheral neuropathy.

—-

Contraindications and Risks

  • Toxicity above 400 ug/day: Selenosis presents as hair loss, nail brittleness, garlic-odor breath, fatigue, irritability, and peripheral neuropathy. Chronic excess may increase type 2 diabetes risk (SELECT trial signal).
  • Selenium-replete populations: No benefit demonstrated in individuals with adequate baseline selenium (>106 ng/mL for prostate cancer; >100 ng/mL generally). The SELECT trial's null result likely reflects supplementation of already-replete American men.
  • U-shaped dose-response: Both deficiency and excess associate with adverse outcomes. "More is not better" applies strongly to selenium.
  • Drug interactions: May potentiate anticoagulant effects; may interact with statins and cisplatin.

—-

Connections

Entities: selenium, copper

Concepts: selenoprotein synthesis, nutritional immunity, oxidative stress, thyroid autoimmunity

Related interventions: vitamin d supplementation (synergistic with Se for Hashimoto's), iron management (thyroid function requires both Se and Fe)

Signatures: hashimotos thyroiditis, graves disease, cardiovascular disease